Literature DB >> 22739645

Value of noncontrast CT immediately after transarterial chemoembolization of hepatocellular carcinoma with drug-eluting beads.

Yosef S Golowa1, Jacob Cynamon, John F Reinus, Milan Kinkhabwala, Mark Abrams, Marcy Jagust, Victoria Chernyak, Andreas Kaubisch.   

Abstract

PURPOSE: To retrospectively evaluate the presence and distribution patterns of contrast agent retention in the liver on noncontrast computed tomography (CT) immediately following chemoembolization with drug-eluting beads (DEBs).
MATERIALS AND METHODS: From 2008 to 2010, 95 patients with 224 liver lesions had chemoembolization performed with DEBs and a noncontrast CT examination of the liver performed immediately after embolization. Of these, 85 patients with 193 lesions were included. The postembolization CT scan was reviewed by a diagnostic radiologist, and the presence of contrast agent retention within the lesion was assessed. Varying patterns of contrast agent retention were defined.
RESULTS: Of the 193 lesions included, 146 (76%) retained contrast medium. Aside from some contrast medium in vessels, very little if any contrast medium was seen in the surrounding liver. Various patterns of contrast agent retention were noted within lesions. In a single case, repeat imaging was obtained 6 hours later, which demonstrated washout of contrast agent in a lesion that had retained contrast agent on the postprocedure CT scan. Of significance, 13 additional foci of contrast agent retention were identified on postchemoembolization CT scans that, on retrospective review of preprocedure imaging, represented enhancing lesions not previously identified.
CONCLUSIONS: Noncontrast CT after chemoembolization with DEBs demonstrates contrast agent retention in 76% of cases, without significant contrast medium seen in the adjacent liver parenchyma. The presence or absence of contrast agent retention may prove to be useful in evaluating accurate targeting of a lesion.
Copyright © 2012 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22739645     DOI: 10.1016/j.jvir.2012.04.020

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  10 in total

Review 1.  Bench-to-clinic development of imageable drug-eluting embolization beads: finding the balance.

Authors:  Andrew L Lewis; Sean L Willis; Matthew R Dreher; Yiqing Tang; Koorosh Ashrafi; Bradford J Wood; Elliot B Levy; Karun V Sharma; Ayele H Negussie; Andrew S Mikhail
Journal:  Future Oncol       Date:  2018-06-26       Impact factor: 3.404

2.  Characterization of a novel intrinsically radiopaque Drug-eluting Bead for image-guided therapy: DC Bead LUMI™.

Authors:  Koorosh Ashrafi; Yiqing Tang; Hugh Britton; Orianne Domenge; Delphine Blino; Andrew J Bushby; Kseniya Shuturminska; Mark den Hartog; Alessandro Radaelli; Ayele H Negussie; Andrew S Mikhail; David L Woods; Venkatesh Krishnasamy; Elliot B Levy; Bradford J Wood; Sean L Willis; Matthew R Dreher; Andrew L Lewis
Journal:  J Control Release       Date:  2017-02-08       Impact factor: 9.776

3.  First Human Experience with Directly Image-able Iodinated Embolization Microbeads.

Authors:  Elliot B Levy; Venkatesh P Krishnasamy; Andrew L Lewis; Sean Willis; Chelsea Macfarlane; Victoria Anderson; Imramsjah Mj van der Bom; Alessandro Radaelli; Matthew R Dreher; Karun V Sharma; Ayele Negussie; Andrew S Mikhail; Jean-Francois H Geschwind; Bradford J Wood
Journal:  Cardiovasc Intervent Radiol       Date:  2016-05-20       Impact factor: 2.740

4.  Mapping Drug Dose Distribution on CT Images Following Transarterial Chemoembolization with Radiopaque Drug-Eluting Beads in a Rabbit Tumor Model.

Authors:  Andrew S Mikhail; William F Pritchard; Ayele H Negussie; Venkatesh P Krishnasamy; Daniel B Amchin; John G Thompson; Paul G Wakim; David Woods; Ivane Bakhutashvili; Juan A Esparza-Trujillo; John W Karanian; Sean L Willis; Andrew L Lewis; Elliot B Levy; Bradford J Wood
Journal:  Radiology       Date:  2018-08-14       Impact factor: 11.105

5.  A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study.

Authors:  Rafael Duran; Karun Sharma; Matthew R Dreher; Koorosh Ashrafi; Sahar Mirpour; MingDe Lin; Ruediger E Schernthaner; Todd R Schlachter; Vania Tacher; Andrew L Lewis; Sean Willis; Mark den Hartog; Alessandro Radaelli; Ayele H Negussie; Bradford J Wood; Jean-François H Geschwind
Journal:  Theranostics       Date:  2016-01-01       Impact factor: 11.556

6.  Transarterial chemoembolization with drug-eluting beads in hepatocellular carcinoma.

Authors:  Hee Chul Nam; Bohyun Jang; Myeong Jun Song
Journal:  World J Gastroenterol       Date:  2016-10-28       Impact factor: 5.742

7.  Sorafenib improves lipiodol deposition in transarterial chemoembolization of Chinese patients with hepatocellular carcinoma: a long-term, retrospective study.

Authors:  Lin Zheng; Chen-Yang Guo; Cheng-Shi Chen; Jin-Cheng Xiao; Hong-Tao Hu; Hong-Tao Cheng; Deng-Wei Zong; Li Jiang; Hai-Liang Li
Journal:  Oncotarget       Date:  2017-06-29

Review 8.  Post Locoregional Therapy Treatment Imaging in Hepatocellular Carcinoma Patients: A Literature-based Review.

Authors:  Shamar Young; Andrew J Taylor; Tina Sanghvi
Journal:  J Clin Transl Hepatol       Date:  2018-02-14

9.  Computed tomography and histopathological findings after embolization with inherently radiopaque 40μm-microspheres, standard 40μm-microspheres and iodized oil in a porcine liver model.

Authors:  Dominik F Vollherbst; Theresa Gockner; Thuy Do; Kerstin Holzer; Carolin Mogler; Paul Flechsig; Alexander Harms; Christopher L Schlett; Philippe L Pereira; Götz M Richter; Hans U Kauczor; Christof M Sommer
Journal:  PLoS One       Date:  2018-07-09       Impact factor: 3.240

Review 10.  Update on Transarterial Chemoembolization with Drug-Eluting Microspheres for Hepatocellular Carcinoma.

Authors:  Yasir M Nouri; Jin Hyoung Kim; Hyun-Ki Yoon; Heung-Kyu Ko; Ji Hoon Shin; Dong Il Gwon
Journal:  Korean J Radiol       Date:  2018-12-27       Impact factor: 3.500

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.